Fibrinolytic Therapy Market By Drug Type (Alteplase, Reteplase, Tenecteplase, Streptokinase, Anistreplase,Urokinase), By Indication (Acute Ischemic Stroke, Acute Myocardial Infarction, Deep Vein Thrombosis, Pulmonary Embolism, Peripheral Arterial Thrombosis, Other Thrombotic Conditions), By End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Others), By Administration (Intravenous (IV), Intra-arterial (IA)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Patient Age (Adult Patients, Pediatric Patients), By Packaging Type (Vials, Ampoules, Pre-filled Syringes), By Application (Emergency Care, Interventional Cardiology, Thrombosis Treatment, Others), By Dosage Form (Lyophilized Powder for Reconstitution, Solution for Injection), By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)
Select a license type that suits your business needs
Single User License
US$ 4,500
US$ 3,500
Three thousand five hundred dollars
Frequently purchased
Multi User License
US$ 7,000
US$ 5,500
Five thousand five hundred dollars
Corporate User License
US$ 10,000
US$ 7,500
Seven thousand five hundred dollars
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients